Meltrin β does not affect the expression of EphA4 on the cell surface nor the initial association between ephrin-A5 and EphA4, but decreases accessibility of antibodies that recognize the EphA4 C-terminus. by Norihiro Yumoto (270290)

Subjects:

TG mice hearts show decreased ISO response. by Mayilvahanan Shanmugam (691549)

A New Rotane Family:  Synthesis, Structure, Conformation, and Dynamics of [3.4]-, [4.4]-, [5.4]-, and [6.4]Rotane¹ by Lutz Fitjer (2466634)

“…At the same time their folding decreases, until in <b>8</b> they are close to planar. …”

RGDfV increases ASM mRNA, ASM activity and ceramide levels and decreases sphingomyelins. by Xiuhai Ren (312555)

Forty-two receptors arranged in order of decreasing interaction with the full set of thirty-five drugs. by Thomas S. Ray (253767)

“…<p>The forty-two receptors are arranged in order of decreasing interaction with the full set of thirty-five drugs, based on the breadth statistics, B, B_sq. and B_exp. …”

RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. by Xiaojuan Li (351842)

Anti-TNF Thioester Glucocorticoid Antibody–Drug Conjugate Fully Inhibits Inflammation with Minimal Effect on Systemic Corticosterone Levels in a Mouse Arthritis Model by Christopher C. Marvin (1338228)

“…Mouse PK indicated that <b>6</b> is cleared 10-fold more rapidly than a first-generation GRM payload, resulting in 10-fold lower exposure and 3-fold decrease in Cmax. …”

Anti-TNF Thioester Glucocorticoid Antibody–Drug Conjugate Fully Inhibits Inflammation with Minimal Effect on Systemic Corticosterone Levels in a Mouse Arthritis Model by Christopher C. Marvin (1338228)

“…Mouse PK indicated that <b>6</b> is cleared 10-fold more rapidly than a first-generation GRM payload, resulting in 10-fold lower exposure and 3-fold decrease in Cmax. …”

<i>Il-17c</i> deletion decreases the expression of inflammatory cytokines. by Giovanna Vella (6413774)

Metformin decreases ATP levels in medium containing low glucose (2.5 mM). by Yongxian Zhuang (634693)

Rictor deletion leads to a decrease in B cells in the PB and spleen. by Yingchi Zhang (607489)

PA sGCβ expression is persistently decreased after neonatal hyperoxia exposure. by Marta Perez (526067)

Positional cloning of <i>qNN1</i> on chromosome 16. by Xinxin Li (281237)

Hematopoietic stem/progenitor cells decreases in the fetal liver of <i>CALM</i>^−/− mice and their colony forming activities are impaired. by Shinya Rai (332061)

Decreased survival of mutants upon treatment with a bacteriostatic antibiotic chloramphenicol by Lisa K Smith (32955)

SPL treatment decreases diabetes-induced co-immunoprecipitation (co-IP) of cldn-4 and -8. by Eduardo Molina-Jijón (4020464)

“…Also, increased co-IP of cldn-8 with cldn-4 was found under diabetic condition and SPL decreased this interaction (C), densitometric analysis show that these changes were significant (D) (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s005" target="_blank">S5 Fig</a>). …”

Gating properties of <i>CACNA1I</i> variants with pooled WT data. by Yousra El Ghaleb (22075892)

Subjects:

JBPOS0101 decreased Amyloid Beta (Aβ) aggregates in the cortex and hippocampal regions in 5xFAD mouse brains. by Jihoon Jeong (4852690)

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10^-5), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10^-5), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10^-22), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10^-71), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10^-28), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10^-12), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10^-10) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10^-17). …”